A 68-year-old male with a new diagnosis of heart failure with reduced ejection fraction (HFrEF) is being evaluated for initiation of guideline-directed medical therapy (GDMT). His vital signs are stable, and he is euvolemic. According to the 2024 ACC Expert Consensus Decision Pathway, which of the following represents the core foundational therapies that should be initiated?
-
A
An ACE inhibitor, a beta-blocker, a loop diuretic, and an aldosterone antagonist.
-
B
An angiotensin receptor blocker (ARB), a beta-blocker, a thiazide diuretic, and digoxin.
-
C
An angiotensin receptor-neprilysin inhibitor (ARNI), an evidence-based beta-blocker, a mineralocorticoid receptor antagonist (MRA), and a sodium-glucose cotransporter-2 (SGLT2) inhibitor.
-
D
A hydralazine/isosorbide dinitrate combination, a beta-blocker, a loop diuretic, and an SGLT2 inhibitor.